Skip to main content
Erschienen in: World Journal of Surgery 9/2017

20.04.2017 | Original Scientific Report

Natural History of MEN1 GEP-NET: Single-Center Experience After a Long Follow-Up

verfasst von: Francesco Giudici, Tiziana Cavalli, Francesca Giusti, Giorgio Gronchi, Giacomo Batignani, Francesco Tonelli, Maria Luisa Brandi

Erschienen in: World Journal of Surgery | Ausgabe 9/2017

Einloggen, um Zugang zu erhalten

Abstract

Background

The multiple endocrine neoplasia type 1 syndrome (MEN1) natural history is poorly evaluated, and few single-institution experiences about hereditary gastroenteropancreatic neuroendocrine tumors (GEP-NET) are reported. Our purpose is to analyze the role of GEP-NET in MEN1-related death, as well as the behavior of these lesions during follow-up.

Methods

The study population consists of 77 patients diagnosed with MEN1 GEP-NET, regularly followed up since 1990. Extensive clinical data were prospectively recorded. Statistical analysis was performed both on the whole population of 77 patients and on two subgroups including patients who, during the long lasting study period, underwent GEP-NET surgery (50 pts) and who did not (27 pts), respectively.

Results

Twenty-five males (32.5%) and 52 females (67.5%) were enrolled. Sixty-four patients had MEN1 family history (83.1%), and genetic mutation was detected in 67 cases (87%). The mean age at GEP-NET diagnosis was 41.4 years (SD = 13.6); 16 patients (20.8%) had GEP-NET diagnosed before age 30 and 12 cases (15.6%) before 1996. The mean interval time between MEN1 diagnosis and GEP-NET detection was 5.7 years (range −11/37; SD = 8.1 years). Overall, the mean follow-up time from MEN1 diagnosis was 15.8 years (SD = 9.7 years) and from GEP-NET diagnosis was 9.6 years (SD = 6.9 years). Gastrinoma was the most frequent functioning GEP-NET and pancreatoduodenectomy the most adopted surgery. GEP-NET progression affected 12 patients within the non-surgical group, while 18 subjects developed progression after surgery.

Conclusions

Our single-center data provide information on epidemiologic, clinical and pathological features of GEP-NET in MEN1 making possible to clarify their natural history.
Literatur
1.
Zurück zum Zitat Larsson C, Skogseid B, Oberg K et al (1988) Multiple endocrine neoplasia type 1 gene maps to chromosome 11 and is lost in insulinoma. Nature 332:85–87CrossRefPubMed Larsson C, Skogseid B, Oberg K et al (1988) Multiple endocrine neoplasia type 1 gene maps to chromosome 11 and is lost in insulinoma. Nature 332:85–87CrossRefPubMed
2.
Zurück zum Zitat Chandrasekharappa SC, Guru SC, Manickam P et al (1997) Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science 276:404–407CrossRefPubMed Chandrasekharappa SC, Guru SC, Manickam P et al (1997) Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science 276:404–407CrossRefPubMed
3.
Zurück zum Zitat Brandi ML, Gagel RF, Angeli A et al (2001) Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 86:5658–5671CrossRefPubMed Brandi ML, Gagel RF, Angeli A et al (2001) Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 86:5658–5671CrossRefPubMed
4.
Zurück zum Zitat Fendrich V, Langer P, Waldmann J et al (2007) Management of sporadic and multiple endocrine neoplasia type 1 gastrinomas. Br J Surg 94:1331–1341CrossRefPubMed Fendrich V, Langer P, Waldmann J et al (2007) Management of sporadic and multiple endocrine neoplasia type 1 gastrinomas. Br J Surg 94:1331–1341CrossRefPubMed
6.
Zurück zum Zitat Marx S, Spiegel AM, Skarulis MC et al (1998) Multiple endocrine neoplasia type 1: clinical and genetic topics. Ann Intern Med 129:484–494CrossRefPubMed Marx S, Spiegel AM, Skarulis MC et al (1998) Multiple endocrine neoplasia type 1: clinical and genetic topics. Ann Intern Med 129:484–494CrossRefPubMed
7.
Zurück zum Zitat Calender A, Cadiot G, Mignon M (2001) Multiple endocrine neoplasia type 1: genetic and clinical aspects. Gastroenterol Clin Biol 25:38–48 Calender A, Cadiot G, Mignon M (2001) Multiple endocrine neoplasia type 1: genetic and clinical aspects. Gastroenterol Clin Biol 25:38–48
8.
Zurück zum Zitat Chanson P, Cadiot G, Murat A (1997) Management of patients and subjects at risk for multiple endocrine neoplasia type 1: MEN 1. GENEM 1. Groupe d’Etude des Néoplasies Endocriniennes Multiples de type 1. Horm Res 47:211–220CrossRefPubMed Chanson P, Cadiot G, Murat A (1997) Management of patients and subjects at risk for multiple endocrine neoplasia type 1: MEN 1. GENEM 1. Groupe d’Etude des Néoplasies Endocriniennes Multiples de type 1. Horm Res 47:211–220CrossRefPubMed
9.
Zurück zum Zitat Lemmens I, Van de Ven WJ, Kas KZ (1997) Identification of the multiple endocrine neoplasia type 1 (MEN1) gene. The European consortium on MEN1. Hum Mol Genet 6:1177–1183CrossRefPubMed Lemmens I, Van de Ven WJ, Kas KZ (1997) Identification of the multiple endocrine neoplasia type 1 (MEN1) gene. The European consortium on MEN1. Hum Mol Genet 6:1177–1183CrossRefPubMed
10.
Zurück zum Zitat Ito T, Igarashi H, Uehara H et al (2013) Causes of death and prognostic factors in multiple endocrine neoplasia type 1: a prospective study: comparison of 106 MEN1/Zollinger–Ellison syndrome patients with 1613 literature MEN1 patients with or without pancreatic endocrine tumors. Med (Baltimore) 92:135–181CrossRef Ito T, Igarashi H, Uehara H et al (2013) Causes of death and prognostic factors in multiple endocrine neoplasia type 1: a prospective study: comparison of 106 MEN1/Zollinger–Ellison syndrome patients with 1613 literature MEN1 patients with or without pancreatic endocrine tumors. Med (Baltimore) 92:135–181CrossRef
11.
Zurück zum Zitat Doherty GM (2003) Multiple endocrine neoplasia type 1: duodenopancreatic tumors. Surg Oncol 12:135–143CrossRefPubMed Doherty GM (2003) Multiple endocrine neoplasia type 1: duodenopancreatic tumors. Surg Oncol 12:135–143CrossRefPubMed
13.
Zurück zum Zitat Hausman MS Jr, Thompson NW, Gauger PG et al (2004) The surgical management of MEN-1 pancreatoduodenal neuroendocrine disease. Surgery 136:1205–1211CrossRefPubMed Hausman MS Jr, Thompson NW, Gauger PG et al (2004) The surgical management of MEN-1 pancreatoduodenal neuroendocrine disease. Surgery 136:1205–1211CrossRefPubMed
14.
15.
Zurück zum Zitat Virgolini I, Ambrosini V, Bomanji JB et al (2010) Procedure guidelines for PET/CT tumour imaging with 68 Ga-DOTA-conjugated peptides: 68 Ga-DOTA-TOC, 68 Ga-DOTA-NOC, 68 Ga-DOTA-TATE. Eur J Nucl Med Mol Imaging 37:2004–2010CrossRefPubMed Virgolini I, Ambrosini V, Bomanji JB et al (2010) Procedure guidelines for PET/CT tumour imaging with 68 Ga-DOTA-conjugated peptides: 68 Ga-DOTA-TOC, 68 Ga-DOTA-NOC, 68 Ga-DOTA-TATE. Eur J Nucl Med Mol Imaging 37:2004–2010CrossRefPubMed
16.
Zurück zum Zitat Wild D, Schmitt JS, Ginj M et al (2003) DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals. Eur J Nucl Med Mol Imaging 30:1338–1347CrossRefPubMed Wild D, Schmitt JS, Ginj M et al (2003) DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals. Eur J Nucl Med Mol Imaging 30:1338–1347CrossRefPubMed
17.
Zurück zum Zitat Tiling N, Ricke J, Wiedenmann B (2002) Neuroendocrine tumors of the gastrointestinal-pancreatic system. Classification and diagnosis. Internist (Berl) 43:210–218CrossRef Tiling N, Ricke J, Wiedenmann B (2002) Neuroendocrine tumors of the gastrointestinal-pancreatic system. Classification and diagnosis. Internist (Berl) 43:210–218CrossRef
18.
Zurück zum Zitat Plöckinger U, Wiedenmann B (2002) Neuroendocrine tumors of the gastro-entero-pancreatic system: the role of early diagnosis, genetic testing and preventive surgery. Dig Dis 20:49–60CrossRefPubMed Plöckinger U, Wiedenmann B (2002) Neuroendocrine tumors of the gastro-entero-pancreatic system: the role of early diagnosis, genetic testing and preventive surgery. Dig Dis 20:49–60CrossRefPubMed
19.
Zurück zum Zitat Lewis RB, Lattin GE Jr, Maj Paal E (2010) Pancreatic endocrine tumors: radiologic-clinicopathologic correlation. Radiographics 30:1445–1464CrossRefPubMed Lewis RB, Lattin GE Jr, Maj Paal E (2010) Pancreatic endocrine tumors: radiologic-clinicopathologic correlation. Radiographics 30:1445–1464CrossRefPubMed
20.
Zurück zum Zitat Pitre J, Soubrane O, Dousset B (1998) Pancreatic echo-endoscopy and preoperative localization of insulinomas. Ann Chir 52:369–373PubMed Pitre J, Soubrane O, Dousset B (1998) Pancreatic echo-endoscopy and preoperative localization of insulinomas. Ann Chir 52:369–373PubMed
21.
Zurück zum Zitat Roland CL, Lo CY, Miller BS (2008) Surgical approach and perioperative complications determine short-term outcomes in patients with insulinoma: results of a bi-institutional study. Ann Surg Oncol 15:3532–3537CrossRefPubMed Roland CL, Lo CY, Miller BS (2008) Surgical approach and perioperative complications determine short-term outcomes in patients with insulinoma: results of a bi-institutional study. Ann Surg Oncol 15:3532–3537CrossRefPubMed
22.
Zurück zum Zitat Pitre J, Soubrane O, Palazzo L (1996) Endoscopic ultrasonography for the preoperative localization of insulinomas. Pancreas 13:55–60CrossRefPubMed Pitre J, Soubrane O, Palazzo L (1996) Endoscopic ultrasonography for the preoperative localization of insulinomas. Pancreas 13:55–60CrossRefPubMed
23.
Zurück zum Zitat McLean A (2004) Endoscopic ultrasound in the detection of pancreatic islet cell tumours. Cancer Imaging 29:84–91CrossRef McLean A (2004) Endoscopic ultrasound in the detection of pancreatic islet cell tumours. Cancer Imaging 29:84–91CrossRef
24.
Zurück zum Zitat Sotoudehmanesh R, Hedayat A, Shirazian N (2007) Endoscopic ultrasonography (EUS) in the localization of insulinoma. Endocrine 31:238–241CrossRefPubMed Sotoudehmanesh R, Hedayat A, Shirazian N (2007) Endoscopic ultrasonography (EUS) in the localization of insulinoma. Endocrine 31:238–241CrossRefPubMed
25.
Zurück zum Zitat Wilkinson S, Teh BT, Davey KR et al (1993) Cause of death in multiple endocrine neoplasia type 1. Arch Surg 128:683–690CrossRefPubMed Wilkinson S, Teh BT, Davey KR et al (1993) Cause of death in multiple endocrine neoplasia type 1. Arch Surg 128:683–690CrossRefPubMed
28.
Zurück zum Zitat Goudet P, Murat A, Binquet C et al (2010) Risk factors and causes of death in MEN1 disease. A GTE (Groupe d’Etude des Tumeurs Endocrines) cohort study among 758 patients. World J Surg 34:249–255. doi:10.1007/s00268-009-0290-1 CrossRefPubMed Goudet P, Murat A, Binquet C et al (2010) Risk factors and causes of death in MEN1 disease. A GTE (Groupe d’Etude des Tumeurs Endocrines) cohort study among 758 patients. World J Surg 34:249–255. doi:10.​1007/​s00268-009-0290-1 CrossRefPubMed
30.
Zurück zum Zitat Thakker RV (2010) Multiple endocrine neoplasia type 1 (MEN1). Best Pract Res Clin Endocrinol Metab 24:355–370CrossRefPubMed Thakker RV (2010) Multiple endocrine neoplasia type 1 (MEN1). Best Pract Res Clin Endocrinol Metab 24:355–370CrossRefPubMed
31.
Zurück zum Zitat Lévy-Bohbot N, Merle C, Goudet P et al (2004) Prevalence, characteristics and prognosis of MEN 1-associated glucagonomas, VIPomas, and somatostatinomas: study from the GTE (Groupe des Tumeurs Endocrines) registry. Gastroenterol Clin Biol 28:1075–1081CrossRefPubMed Lévy-Bohbot N, Merle C, Goudet P et al (2004) Prevalence, characteristics and prognosis of MEN 1-associated glucagonomas, VIPomas, and somatostatinomas: study from the GTE (Groupe des Tumeurs Endocrines) registry. Gastroenterol Clin Biol 28:1075–1081CrossRefPubMed
32.
Zurück zum Zitat Lips CJ, Vasen HF, Lamers CB (1984) Multiple endocrine neoplasia syndromes. Crit Rev Oncol Hematol 2:117–184CrossRefPubMed Lips CJ, Vasen HF, Lamers CB (1984) Multiple endocrine neoplasia syndromes. Crit Rev Oncol Hematol 2:117–184CrossRefPubMed
33.
Zurück zum Zitat Ekeblad S, Skogseid B, Dunder K et al (2008) Prognostic factors and survival in 324 patients with pancreatic endocrine tumor treated at a single institution. Clin Cancer Res 14:7798–7803CrossRefPubMed Ekeblad S, Skogseid B, Dunder K et al (2008) Prognostic factors and survival in 324 patients with pancreatic endocrine tumor treated at a single institution. Clin Cancer Res 14:7798–7803CrossRefPubMed
34.
Zurück zum Zitat Cougard P, Goudet P, Peix JL et al (2000) Insulinomas in multiple endocrine neoplasia type 1. Report of a series of 44 cases by the multiple endocrine neoplasia study group. Ann Chir 125:118–123CrossRefPubMed Cougard P, Goudet P, Peix JL et al (2000) Insulinomas in multiple endocrine neoplasia type 1. Report of a series of 44 cases by the multiple endocrine neoplasia study group. Ann Chir 125:118–123CrossRefPubMed
35.
Zurück zum Zitat Skogseid B, Rastad J, Gobl A et al (1995) Adrenal lesion in multiple endocrine neoplasia type 1. Surgery 118:1077–1082CrossRefPubMed Skogseid B, Rastad J, Gobl A et al (1995) Adrenal lesion in multiple endocrine neoplasia type 1. Surgery 118:1077–1082CrossRefPubMed
Metadaten
Titel
Natural History of MEN1 GEP-NET: Single-Center Experience After a Long Follow-Up
verfasst von
Francesco Giudici
Tiziana Cavalli
Francesca Giusti
Giorgio Gronchi
Giacomo Batignani
Francesco Tonelli
Maria Luisa Brandi
Publikationsdatum
20.04.2017
Verlag
Springer International Publishing
Erschienen in
World Journal of Surgery / Ausgabe 9/2017
Print ISSN: 0364-2313
Elektronische ISSN: 1432-2323
DOI
https://doi.org/10.1007/s00268-017-4019-2

Weitere Artikel der Ausgabe 9/2017

World Journal of Surgery 9/2017 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.